These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 18957629)

  • 1. Choice of comparator in active control trials of new drugs.
    van Luijn JC; van Loenen AC; Gribnau FW; Leufkens HG
    Ann Pharmacother; 2008 Nov; 42(11):1605-12. PubMed ID: 18957629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization.
    van Luijn JC; Gribnau FW; Leufkens HG
    Br J Clin Pharmacol; 2007 Feb; 63(2):159-62. PubMed ID: 17166187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparators (medicinal and non medicinal) for marketing authorization, for public health, for payers and at the European level.
    Berdaï D; Hotton JM; Lechat P;
    Therapie; 2010; 65(4):329-34. PubMed ID: 20854755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gap in publication of comparative information on new medicines.
    van Luijn JC; Stolk P; Gribnau FW; Leufkens HG
    Br J Clin Pharmacol; 2008 May; 65(5):716-22. PubMed ID: 18294324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical evaluation of efficacy and adverse effects in the (European) registration of drugs: what does it mean for the doctor and patient?].
    Koopmans PP; de Graeff PA; van Zwieten-Boot BJ; Lekkerkerker JF; Broekmans AW
    Ned Tijdschr Geneeskd; 2000 Apr; 144(16):756-61. PubMed ID: 10812445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Superior efficacy of new medicines?
    van Luijn JC; Gribnau FW; Leufkens HG
    Eur J Clin Pharmacol; 2010 May; 66(5):445-8. PubMed ID: 20224944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
    Reeve LM
    Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interpretation and inference in noninferiority randomized controlled trials in drug research.
    Wangge G; Klungel OH; Roes KC; de Boer A; Hoes AW; Knol MJ
    Clin Pharmacol Ther; 2010 Sep; 88(3):420-3. PubMed ID: 20668448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Approval probabilities and regulatory review patterns for anticancer drugs in the European Union.
    Hartmann M; Mayer-Nicolai C; Pfaff O
    Crit Rev Oncol Hematol; 2013 Aug; 87(2):112-21. PubMed ID: 23433721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Sense and nonsense in post-authorization surveillance].
    de Mey C
    Med Klin (Munich); 2000 May; 95(1 Spec No):77-82. PubMed ID: 10851853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Designing clinical trials for the treatment of delirium.
    Trzepacz PT; Bourne R; Zhang S
    J Psychosom Res; 2008 Sep; 65(3):299-307. PubMed ID: 18707954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The place of a new drug in the therapeutic strategy].
    Castaigne A; Goehrs JM; Ravoire S
    Therapie; 1999; 54(4):463-70. PubMed ID: 10667112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Important issues in the justification of a control treatment in paediatric drug trials.
    Kelly LE; Davies EH; Saint-Raymond A; Tomasi P; Offringa M
    Arch Dis Child; 2016 Oct; 101(10):962-7. PubMed ID: 27052950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The year's new drugs and biologics--2006.
    Graul AI; Sorbera LA; Bozzo J; Serradell N; Revel L; Prous JR
    Drug News Perspect; 2007; 20(1):17-44. PubMed ID: 17332898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New preparations comprising recombinant human growth hormone: deliberations on the issue of biosimilars.
    Ranke MB
    Horm Res; 2008; 69(1):22-8. PubMed ID: 18057913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Similar biological medicinal products containing recombinant human growth hormone: European regulation.
    Pavlovic M; Girardin E; Kapetanovic L; Ho K; Trouvin JH
    Horm Res; 2008; 69(1):14-21. PubMed ID: 18059081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Choosing a control intervention for a randomised clinical trial.
    Mann H; Djulbegovic B
    BMC Med Res Methodol; 2003 Apr; 3():7. PubMed ID: 12709266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.